Herpes Zoster

Clinics in Geriatric Medicine

Volumn 32, Issue 3, 2016, Pages 539-553

  Schmader, Kenneth ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Aged; Elderly; Herpes zoster; Postherpetic neuralgia; Varicella zoster virus

Indexed keywords

ACICLOVIR; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANXIOLYTIC AGENT; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FAMCICLOVIR; GABAPENTIN; HYPNOTIC SEDATIVE AGENT; LIDOCAINE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXYCODONE; PLACEBO; PREDNISONE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALACICLOVIR; VARICELLA ZOSTER VACCINE; ANTIVIRUS AGENT;

ACUPUNCTURE; ANTIVIRAL ACTIVITY; ATAXIA; CHRONIC PAIN; CLINICAL FEATURE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; CRYOTHERAPY; DAILY LIFE ACTIVITY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COMPETITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; EVENING DOSAGE; GRANULOCYTOSIS; HEADACHE; HEART ARRHYTHMIA; HEART BLOCK; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; INJECTION SITE REACTION; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROSURGERY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PRURITUS; QUALITY OF LIFE; RASH; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SKIN REDNESS; SOMNOLENCE; SPINAL CORD STIMULATION; TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION; URINE RETENTION; VACCINATION; VOMITING; XEROSTOMIA; ADULT; GLOBAL HEALTH; MORBIDITY; VARICELLA ZOSTER VIRUS; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; GLOBAL HEALTH; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MORBIDITY;

EID: 84963625438     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2016.02.011     Document Type: Review

References (43)

1. 1 Cohen, J.I., The varicella-zoster virus genome. Curr Top Microbiol Immunol 342 (2010), 1–14.
2. 2 Yawn, B.P., Saddier, P., Wollan, P.C., et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82 (2007), 1341–1349.
3. 3 Pinchinat, S., Cebrian-Cuenca, A.M., Bricout, H., et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis, 13, 2013, 170.
4. 4 Oxman, M.N., Levin, M.J., Johnson, G.R., et al., For the Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005), 2271–2284.
5. 5 Harpaz, R., Ortega-Sanchez, I.R., Seward, J.F., et al., Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 57:RR-5 (2008), 1–30.
6. 6 Cohen, J.I., Herpes zoster. N Engl J Med 369 (2013), 255–263.
7. 7 Yawn, B.P., Wollan, P.C., Kurland, M.J., et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 86 (2011), 88–93.
8. 8 Tseng, H.F., Chi, M., Smith, N., et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 206 (2012), 190–196.
9. 9 Winthrop, K.L., Baddley, J.W., Chen, L., et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 309 (2013), 887–895.
10. 10 Schmader, K.E., George, L.K., Hamilton, J.D., Racial differences in the occurrence of herpes zoster. J Infect Dis 171 (1995), 701–705.
11. 11 Zhang, J.X., Joesoef, R.M., Bialek, S., et al. Association of physical trauma with risk of herpes zoster among Medicare beneficiaries in the United States. J Infect Dis 207 (2013), 1007–1011.
12. 12 Hales, C.M., Harpaz, R., Joesoef, M.R., et al. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med 159 (2013), 739–745.
13. 13 Viner, K., Perella, D., Lopez, A., et al. Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings. J Infect Dis 205 (2012), 1336–1341.
14. 14 Katz, J., Cooper, E.M., Walther, R.R., et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 39 (2004), 342–348.
15. 15 Schmader, K.E., Sloane, R., Pieper, C., et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 23 (2007), 490–497.
16. 16 Jung, B.F., Johnson, R.W., Griffin, D.R., et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 62 (2004), 1545–1551.
17. 17 Harbecke, R., Oxman, M.N., Arnold, B.A., et al. A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol 81 (2009), 1310–1322.
18. 18 Dworkin, R.H., Johnson, R.W., Breuer, J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 44 (2007), S1–S26.
19. 19 Dworkin, R.H., Barbano, R.L., Tyring, S.K., et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 142 (2009), 209–217.
20. 20 Esmann, V., Geil, J.P., Kroon, S., et al. Prednisolone does not prevent postherpetic neuralgia. Lancet 2 (1987), 126–129.
21. 21 Wood, M.J., Johnson, R.W., McKendrick, M.W., et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 330 (1994), 896–900.
22. 22 Whitley, R.J., Weiss, H., Gnann, J.W., et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 125 (1996), 376–383.
23. 23 Berry, J.D., Petersen, K.L., A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 65 (2005), 444–447.
24. 24 van Wijck, A.J.M., Opstelten, W., Moons, K.G., et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 367 (2006), 219–224.
25. 25 Johnson, R.W., Rice, A.S., Postherpetic neuralgia. N Engl J Med 371 (2014), 1526–1533.
26. 26 NICE clinical guideline 173, Neuropathic pain—pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings. 2013, National Institute for Health and Care Excellence, London Available at: http://guidance.nice.org.uk/CG173.
27. 27 Dworkin, R.H., O'Connor, A.B., Audette, J., et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85:Suppl (2010), S3–S14.
28. 28 Watson, C.P.N., Vernich, L., Chipman, M., et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 51 (1998), 1166–1171.
29. 29 Raja, S.N., Haythornthwaite, J.A., Pappagallo, M., et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 59 (2002), 1015–1021.
30. 30 Gilron, I., Bailey, J.M., Tu, D., et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 (2005), 1324–1334.
31. 31 Gilron, I., Bailey, J.M., Tu, D., et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 374 (2009), 1252–1261.
32. 32 Weiner, D.K., Schmader, K.E., Postherpetic pain: more than sensory neuralgia?. Pain Med 7 (2006), 243–249.
33. 33 Tseng, H.F., Smith, N., Harpaz, R., et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 305 (2011), 160–166.
34. 34 Langan, S.M., Smeeth, L., Margolis, D., et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med, 10(4), 2013, e1001420.
35. 35 Schmader, K.E., Johnson, G.R., Saddier, P., et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality of life measures in older adults. J Am Geriatr Soc 58 (2010), 1634–1641.
36. 36 Tseng, H.F., Tartof, S., Harpaz, R., et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis 59 (2014), 913–919.
37. 37 Simberkoff, M.S., Arbeit, R.D., Johnson, G.R., et al., For the Shingles Prevention Study Group. Safety of the herpes zoster vaccine in the Shingles Prevention Study: a randomized trial. Ann Intern Med 152 (2010), 545–554.
38. 38 Tseng, H.F., Liu, A., Sy, L., et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med 271 (2012), 510–520.
39. 39 Schmader, K.E., Oxman, M.N., Levin, M.J., et al., For the Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 55 (2012), 1320–1328.
40. 40 Morrison, V.A., Oxman, M.N., Johnson, G., et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 60 (2015), 900–909.
41. 41 Schmader, K.E., Levin, M.J., Gnann, J.W., et al. Efficacy, safety, tolerability of herpes zoster vaccine in persons 50-59 years of age. Clin Infect Dis 54 (2012), 922–928.
42. 42 Hales, C.M., Harpaz, R., Ortega-Sanchez, I., et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep 63:33 (2014), 729–731.
43. 43 Lal, H., Cunningham, A.L., Godeaux, O., et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:22 (2015), 2087–2096.